CSIMarket


Anika Therapeutics Inc   (ANIK)
Other Ticker:  
 


 

Anika Therapeutics Inc

ANIK's Financial Statements and Analysis



Anika Therapeutics Inc increased forth quarter of 2023 net loss per share of $-4.29 compare to net loss per share of $-0.34 recorded in the same quarter a year ago a decrease compare to $-0.45 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -4.29 $  43 Mill
$-3.95     $+4M     +9.15 %



Anika Therapeutics Inc 's Revenue rose by 9.15 % in forth quarter of 2023 (Dec 31 2023) year on year, to $43 million and advanced by 5.63 % sequentially.


Anika Therapeutics Inc is

More on ANIK's Income Statement



Anika Therapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-63.000 million, an increase from net loss of $-4.908 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on ANIK's Growth

Anika Therapeutics Inc Inventories
Inventories grew by 16.65 % to $46 million from IV. Quarter a year ago, sequentially inventories rose by 6.09 %. ANIK's Cash flow In the forth quarter of 2023 company's net cash flow was $2 million

More on ANIK's Cash flow Statement


Anika Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Anika Therapeutics Inc payed $ -0.12 cash per share, on a free-cash flow basis .

Book value fell by -21.64 % sequentially to $14.48 per share, -70.91% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value grew to $ 13.65 per share from $ 13.29.

Company issued 0.02 million shares or 0.15 % in Dec 31 2023.


More on ANIK's Dividends

 Market Capitalization (Millions) 370
 Shares Outstanding (Millions) 15
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 166
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) -5
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 187




Anika Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Anika Therapeutics Inc had negative $ -0.12 cash flow per share, on a free-cash flow basis .

Book value fell by -21.64 % sequentially to $14.48 per share, -70.91% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value grew to $ 13.65 per share from $ 13.29.

Company issued 0.02 million shares or 0.15 % in Dec 31 2023.


More on ANIK's Balance Sheets

 Market Capitalization (Millions) 370
 Shares Outstanding (Millions) 15
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 166
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) -5
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 187
   


  News about Anika Therapeutics Inc Earnings

Stock inducement grants impact Anika Therapeutics Inc.'s share structure and stock price



In the dynamic world of the stock market, it is crucial for investors to stay informed about the financial performance and significant developments of companies. Anika Therapeutics Inc., a global joint preservation company in early intervention orthopedics, recently reported its financial results for the October to December 31, 2023, financial period. This article will highlight key observations from the company's financial report and analyze the impact of stock inducement grants on its current share structure and stock price.
Financial Performance Overview:
During the October to December 2023 financial period, Anika Therapeutics Inc. witnessed a significant increase in revenue, reaching $4...

Anika Therapeutics Inc Reveals Impressive 1.689% Revenue Surge, Pointing towards Promising Future

The stock market can be a volatile and unpredictable place, with ups and downs that can leave investors feeling uncertain. However, there are times when the numbers align and a company's performance shows great potential. Anika Therapeutics Inc is one such company that has caught the attention of many investors. Despite the recent deficit, there are optimistic signs that suggest a bright future lies ahead.
In the most recent fiscal period, Anika Therapeutics Inc reported a deficit per share of $-0.45, an increase from the $-0.29 per share deficit experienced a year ago. While this increase might initially raise concerns, it is important to note that growth often comes with some temporary setbacks. It's c...

Anika Therapeutics Inc Reports Double-Digit Revenue Growth in Second Quarter of 2023



Anika Therapeutics Inc, a renowned company in the Medical Equipment and Supplies sector, recently reported its financial results for the period ending June 30, 2023. The results demonstrate significant improvements in various key metrics, such as earnings per share (EPS) and revenue. This article will delve into the details of the financial results and provide context by analyzing the company's stock performance.
Financial Results:
1. Earnings per Share (EPS):
In June 2023, Anika Therapeutics Inc reduced its loss per share to $-0.19 compared to $-0.20 in the previous year. This improvement shows the company's progress in managing its losses and moving towards profitability. Additionally...

Anika Therapeutics Inc's Remarkable Resilience: 3.355% Revenue Boost Amidst Challenging Times in Q1 2023

Anika Therapeutics Inc is a Medical Equipment and Supplies company that specializes in the development and manufacturing of innovative therapeutic products for tissue healing, regeneration, and repair. The company was founded in 1992 and is headquartered in Bedford, Massachusetts. Anika Therapeutics Inc has gained a reputation for developing high-quality, safe and effective products that are widely used by healthcare professionals around the world.
For the financial first quarter of 2023, Anika Therapeutics Inc reported a net deficit per share of $-0.71, compared to $-0.20 a year prior. This represents a significant decline in earnings per share, which can be attributed to various factors such as rising ...


Date modified: 2024-03-18T21:21:52+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com